News | April 01, 2025
Lonza implements streamlined operating model
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Subscribe To Our Newsletter & Stay Updated
